A new study found users who take the drug-made by Pfizer- for a year or more are 3.5 times more likely to develop a meningioma, the most common type of brain tumour.

Patients on Itovebi plus Ibrance and fulvestrant had improved progression-free and overall survival compared to Ibrance-fulvestrant alone.

Lee, at this point in the year, all the companies that pay dividends have pretty much set their dividends. You know, the ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

IPG is pretty much holding it together as it waits to complete its merger with Omnicom, reporting a 3.5% decline in organic ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

The panelists said that vaginal creams and other localized therapies for menopause are safe and vastly underused by women who could benefit.

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private ...

Shares of Pfizer Inc. PFE rallied 3.63% to $25.14 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...